• CNIO recruits Manuel Valiente, a brain metastasis expert
  12.03.2015
  Manuel Valiente, an expert in brain metastasis —a process by which cancer cells spread to the brain from other parts of the body—, will start a new research group at the Spanish National Cancer Research Centre (CNIO). After working for five years at the Memorial Sloan-Kettering Cancer Center in New York with one of the […]
• CNIO scientists link aggressiveness of chronic lymphocytic leukaemia to genetic variability
  05.02.2015
  The genetic variability of a tumour could be a predictor for its aggressiveness: the greater the variability in gene expression, the more aggressive the tumour is likely to be. This is the hypothesis that the CNIO Structural Biology and Biocomputing Programme, led by Alfonso Valencia, is testing, after their findings on chronic lymphocytic leukaemia (CLL), […]
• CNIO scientists discover new blood platelet formation mechanism
  26.01.2015
  Thrombocytopenia is a disease characterised by a lower platelet level than normal. Platelets are tiny cells that participate in the coagulation of blood. Patients usually suffer uncontrolled bleeding that gives rise to hematomas and haemorrhages, and even death. Understanding how these cells are produced by the body, then, could be of great use for alleviating […]
• Manuel Serrano joins the Royal Academy of Medicine as a Corresponding Member
  16.01.2015
  Manuel Serrano, Director of the Molecular Oncology Programme at the Spanish National Cancer Research Centre (CNIO), has been awarded with the Royal Academy of Medicine (RAMN) 2014 Award, becoming a Corresponding Member of the institution.His designation was announced during the opening ceremony of the academic year at the RAMN. Professor Joaquín Poch, the President of […]
• CNIO scientist associate rare variants of a gene with side effects from chemotherapy with paclitaxel
  14.01.2015
  Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. Symptoms include tingling and pain in the extremities, cramping, muscular weakness and difficulty walking, in […]
• Spain to become a full member of Elixir, the European infrastructure for bioinformatics
  17.12.2014
  Spain will become a full member of ELIXIR, the European bioinformatics infrastructure created to optimise biological data obtained from life sciences research. Spain participates in ELIXIR through the National Bioinformatics Institute (INB), a platform of the National Institute of Health Carlos III (ISCIII), whose central node is hosted at the Spanish National Cancer Research Centre […]
• ‘CNIO Friends’ invites society to join forces against cancer
  09.12.2014
  Public perception reports for science show a growing interest in society towards patronage and new forms of citizen participation in research and science, particularly in the areas of medicine and health. Specifically, in the field of oncology, dedication and hard work in research and development is what allows us to say that, nowadays, nearly half […]
• CNIO team has visualised the DNA double-strand break process visualised for the first time
  08.12.2014
  Scientists from the Spanish National Cancer Research Centre (CNIO), led by Guillermo Montoya, have developed a method for producing biological crystals that has allowed scientists to observe —for the first time— DNA double chain breaks. They have also created a computer simulation that makes this process, which lasts in the order of millionths of a […]
• “Lab Day 2014: A day of celebration by and for the CNIO”
  04.12.2014
  Next Tuesday, December 9th, the Spanish National Cancer Research Centre (CNIO) celebrates its fourth Lab Day. The event, organised by the Office of Academic Affairs (Dean’s Office) with CNIO pre-doctoral (CNIOSA) and postdoctoral (CNIO?PDA) researchers, is designed to promote interactions between different research groups and to give visibility to their work.In the words of the […]